With its NURA project, SCK CEN significantly increases its contribution to the fight against cancer. By pooling its knowledge and expertise in terms of radiopharmaceuticals, NURA contributes to the development of the next-generation radiopharmaceuticals. More specifically, NURA performs game-changing research into radiopharmaceuticals for treating different types of cancer in cooperation with clinical and industrial partners.
SCK CEN works actively on the design and construction of a new multi-purpose research plant: MYRRHA, which stands for Multi-purpose HYbrid Research Reactor for High-tech Applications. MYRRHA is a versatile research infrastructure but above all unique. It is the world's first research reactor driven by a particle accelerator.
With the public-public partnership RECUMO, SCK CEN and the National Institute for Radio Elements (IRE) reach out to one another. SCK CEN will decontaminate the current and future highly radioactive residues and thus reduce the stock. In this way, RECUMO contributes to the security of supply of medical radio-isotopes, which are indispensable in the fight against cancer.